Busca avançada
Ano de início
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Development of Equine IgG Antivenoms against Major Snake Groups in Mozambique

Texto completo
Guidolin, Felipe Raimondi [1] ; Caricati, Celso Pereira [1] ; Marcelino, Jose Roberto [2] ; da Silva, Wilmar Dias [3]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Inst Butantan, Lab Especial Piloto Pesquisa & Desenvolvimeto Imu, Sao Paulo - Brazil
[2] Inst Butantan, Div Desenvolvimento Tecnol & Prod Soros Hiperimun, Sao Paulo - Brazil
[3] Inst Butantan, Lab Imunoquim, Sao Paulo - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: PLoS Neglected Tropical Diseases; v. 10, n. 1 JAN 2016.
Citações Web of Science: 2

Background Snake envenoming is a significant public health problem in underdeveloped and developing countries. In sub-Saharan Africa, it is estimated that 90,000-400,000 envenomations occur each year, resulting in 3,500-32,000 deaths. Envenomings are caused by snakes from the Viperidae (Bitis spp. and Echis spp.) and Elapidae (Naja spp. and Dendroaspis spp.) families. The African continent has been suffering from a severe antivenom crisis and current antivenom production is only sufficient to treat 25% of snakebite cases. Our aim is to develop high-quality antivenoms against the main snake species found in Mozambique. Methods Adult horses primed with the indicated venoms were divided into 5 groups (B. arietans; B. nasicornis + B. rhinoceros; N. melanoleuca; N. mossambica; N. annulifera + D. polylepis + D. angusticeps) and reimmunized two times for antivenom production. Blood was collected, and plasma was separated and subjected to antibody purification using caprylic acid. Plasmas and antivenoms were subject to titration, affinity determination, cross-recognition assays and in vivo venom lethality neutralization. A commercial anti-Crotalic antivenom was used for comparison. Results The purified antivenoms exhibited high titers against B. arietans, B. nasicornis and B. rhinoceros (5.18 x 10(6), 3.60 x 10(6) and 3.50 x 10(6) U-E/mL, respectively) and N. melanoleuca, N. mossambica and N. annulifera (7.41 x 10(6), 3.07 x 10(6) and 2.60 x 10(6) U-E/mL, respectively), but lower titers against the D. angusticeps and D. polylepis (1.87 x 10(6) and 1.67 x 10(6) U-E/mL). All the groups, except anti-N. melanoleuca, showed significant differences from the anti-Crotalic antivenom (7.55 x 10(6) U-E/mL). The affinity index of all the groups was high, ranging from 31% to 45%. Cross-recognition assays showed the recognition of proteins with similar molecular weight in the venoms and may indicate the possibility of paraspecific neutralization. The three monospecific antivenoms were able to provide in vivo protection. Conclusion Our results indicate that the anti-Bitis and anti-Naja antivenoms developed would be useful for treating snakebite envenomations in Mozambique, although their effectiveness should to be increased. We propose instead the development of monospecific antivenoms, which would serve as the basis for two polyvalent antivenoms, the anti-Bitis and anti-Elapidae. Polyvalent antivenoms represent an increase in treatment quality, as they have a wider range of application and are easier to distribute and administer to snake envenoming victims. (AU)

Processo FAPESP: 13/07467-1 - CeTICS - Centro de Toxinas, Imuno-Resposta e Sinalização Celular
Beneficiário:Hugo Aguirre Armelin
Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs